Skip to main content
Premium Trial:

Request an Annual Quote

Your Modesty Becomes You ... But Doesn't Really Help

The latest issue of the Economist explores whether Europe's biotech sector is finally poised for a breakthrough. "For decades the continent's scientific elite watched as boffins in America fled academia to start biotech firms," the article says. "Europe failed to produce a rival to America's Amgen or Genentech." The story focuses on Lisa Drakeman, an American CEO of Genmab, one of Europe's biggest biotechs with a market cap of $2.5 billion. While some indicators suggest that Europe may be on the verge of becoming a major player in the field, there's still a perception that "European technology start-ups fail to think big in contrast with the outsized egos in Silicon Valley."

 

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.